Drug/Small Molecule:
minocycline

2D structure

Overview

Generic Names: minocycline
IUPAC Name: (2Z,4S,4aS,5aR,12aS)-2-(amino-hydroxymethylidene)-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
Trade Names: Alti-Minocycline; Apo-Minocycline; Arestin; Dynacin; Gen-Minocycline; Klinomycin; Minociclina [INN-Spanish]; Minocin; Minocyclin; Minocycline HCl; Minocyclinum [INN-Latin]; Minocyn; Minomycin; Novo-Minocycline; Solodyn; Vectrin
PharmGKB Accession Id: PA450519

Description

A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. [PubChem]

Indication

For the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by Streptococcus pneumoniae and for the treatment of asymptomatic carriers of Neisseria meningitidis.

ATC Therapeutic Categories

  • A01AB:Antiinfectives and antiseptics for local oral treatment
  • J01AA:Tetracyclines

Pharmacology and Interactions

Mechanism Of Action

Minocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Tetracyclines like minocycline bind to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.

Pharmacology

Minocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.

Food Interactions

Calcium and iron needs increased with long term use. Do not take Aluminum or magnesium antacids or supplements while on this medication. Take with food.

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic.

Protein Binding

55% to 76%

Absorption

Rapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.

Half Life

11-22 hours

Toxicity

Minocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD50=2380 mg/kg (rat, oral), LD50=3600 mg/kg (mouse, oral)

Chemical Properties

Chemical Formula:

C23H27N3O7

SMILES Code:

CN(C)c1ccc(c2c1C[C@H]3C[C@H]4[C@@H](C(=C(C(=O)[C@]4(C(=C3C2=O)O)O)C(=O)N)O)N(C)C)O

(Format: OpenEye Isomeric)

Molecular Weight ( average / monoisotopic )

457.4764 / 457.1849

Non-Curated Information

A list of non-curated publications that mention this drug along with other genes is available.

Drug Targets

Non-Curated Information

A list of non-curated publications that mention this drug along with other drugs is available.

Drug Interactions

acenocoumarol The tetracycline increases the anticoagulant effect
acitretin Increased risk of intracranial hypertension
aluminium Formation of non-absorbable complexes
amoxicillin Possible antagonism of action
ampicillin Possible antagonism of action
anisindione The tetracycline increases the anticoagulant effect
attapulgite Formation of non-absorbable complexes
azlocillin Possible antagonism of action
aztreonam Possible antagonism of action
bacampicillin Possible antagonism of action
bismuth Formation of non-absorbable complexes
bismuth subsalicylate Formation of non-absorbable complexes
calcium Formation of non-absorbable complexes
carbenicillin Possible antagonism of action
clavulanate Possible antagonism of action
cloxacillin Possible antagonism of action
cyclacillin Possible antagonism of action
dicloxacillin Possible antagonism of action
dicumarol The tetracycline increases the anticoagulant effect
digoxin The tetracycline increases the effect of digoxin in 10% of patients
ethinyl estradiol This anti-infectious agent could decrease the effect of the oral contraceptive
etretinate Increased risk of intracranial hypertension
flucloxacillin Possible antagonism of action
hetacillin Possible antagonism of action
insulin The tetracycline increases the risk of hypoglycemia
iron Formation of non-absorbable complexes
isotretinoin This anti-infectious agent could decrease the effect of the oral contraceptive
magnesium Formation of non-absorbable complexes
magnesium oxide Formation of non-absorbable complexes
mestranol This anti-infectious agent could decrease the effect of the oral contraceptive
methicillin acyl-serine Possible antagonism of action
methoxyflurane The tetracycline increases the renal toxicity of methoxyflurane
mezlocillin Possible antagonism of action
nafcillin Possible antagonism of action
oxacillin Possible antagonism of action
penicillin g Possible antagonism of action
penicillin v Possible antagonism of action
piperacillin Possible antagonism of action
pivampicillin Possible antagonism of action
pivmecillinam Possible antagonism of action
salicylate-magnesium Formation of non-absorbable complexes
tazobactam Possible antagonism of action
ticarcillin Possible antagonism of action
trisalicylate-choline Formation of non-absorbable complexes
warfarin The tetracycline increases the anticoagulant effect
zinc Formation of non-absorbable complexes

Non-Curated Information

A list of non-curated publications that mention this drug along with other diseases is available.

Additional Datasets

These datasets are minimally curated and are sorted alphabetically by title.

  1. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB01017
KEGG Compound ID:
C07225
KEGG Drug ID:
D05045
PubChem Compound ID:
5281021
PubChem Substance ID:
167749

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Non-Curated Publications

A list of non-curated publications that mention this drug is available.

PharmGKB integrates drug information from different sources: DrugBank, Open Eye Scientific Software.
The PharmGKB is financially supported by the NIH/ NIGMS and is managed at Stanford University (U01GM61374).
©2001-2010 PharmGKB.